| 索拉非尼防治肝癌微血管侵犯的研究进展 |
| |
| 作者姓名： | 毕新宇 |
| |
| 作者单位： | 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院肝胆外科,北京,100021 |
| |
| 基金项目： | 中国传染病国家重点项目,项目 |
| |
| 摘 要： | 微血管侵犯是肝细胞肝癌患者预后不良的危险因素,通常依靠术后病理检测明确。目前对于伴有微血管侵犯的肝细胞肝癌患者其术后辅助治疗方面缺乏充分的临床证据。索拉非尼是一种多激酶抑制剂,主要用于用于无法手术或伴有远处转移的晚期肝细胞肝癌患者。本文将对索拉非尼用于伴有微血管侵犯的肝细胞肝癌患者的术后辅助治疗方面的研究进展进行简要介绍。
|
| 关 键 词： | 肝细胞肝癌 微血管侵犯 索拉非尼 辅助治疗 |
Recent progress of sorafenib in adjuvant treatment of hepatocellular carcinoma with microvascular invasion |
| |
| Authors: | BI Xin-yu |
| |
| Institution: | (Department of Hepatobiliary Surgery,National Cancer Center/Cancer Hospital,Chinese Academy of Medicai Sciencee and Pekine Union Medicai College,Beijing 100021) |
| |
| Abstract: | Microvascular invasion is a risk factor for poor prognosis in patients with hepatocellular carcinoma,and is usually determined by postoperative pathological examination.There is currently insufficient clinical evidence for postoperative adjuvant therapy in hepatocellular carcinoma patients with microvascular invasion.Sorafenib is a multi-kinase inhibitor used primarily in patients with advanced hepatocellular carcinoma who are inoperable or have distant metastases.This article will briefly introduce the research progress of sorafenib for postoperative adjuvant therapy in patients with hepatocellular carcinoma with microvascular invasion. |
| |
| Keywords: | Hepatocellular Carcinoma Microvascular invasion Sorafenib Adjuvant treatment |
| 本文献已被 维普 万方数据 等数据库收录！ |
